Tectonic Therapeutic, Inc. (TECX)
20.80
+0.15
(+0.73%)
USD |
NASDAQ |
Oct 19, 14:43
Tectonic Therapeutic Enterprise Value : 174.54M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 174.54M |
| October 15, 2026 | 187.04M |
| October 14, 2026 | 180.50M |
| October 13, 2026 | 187.23M |
| October 12, 2026 | 207.24M |
| October 09, 2026 | 226.09M |
| October 08, 2026 | 214.93M |
| October 07, 2026 | 214.16M |
| October 06, 2026 | 208.39M |
| October 05, 2026 | 221.86M |
| October 02, 2026 | 210.89M |
| October 01, 2026 | 213.39M |
| September 30, 2026 | 225.32M |
| September 29, 2026 | 226.28M |
| September 28, 2026 | 229.55M |
| September 25, 2026 | 232.63M |
| September 24, 2026 | 241.28M |
| September 23, 2026 | 257.83M |
| September 22, 2026 | 287.06M |
| September 21, 2026 | 289.56M |
| September 18, 2026 | 296.68M |
| September 17, 2026 | 300.72M |
| September 16, 2026 | 314.19M |
| September 15, 2026 | 325.73M |
| September 14, 2026 | 348.81M |
| Date | Value |
|---|---|
| September 11, 2026 | 336.11M |
| September 10, 2026 | 327.65M |
| September 09, 2026 | 363.62M |
| September 08, 2026 | 362.08M |
| September 04, 2026 | 368.81M |
| September 03, 2026 | 352.85M |
| September 02, 2026 | 361.70M |
| September 01, 2026 | 377.85M |
| August 31, 2026 | 353.23M |
| August 28, 2026 | 462.49M |
| August 27, 2026 | 483.26M |
| August 26, 2026 | 469.22M |
| August 25, 2026 | 502.69M |
| August 24, 2026 | 478.84M |
| August 21, 2026 | 501.15M |
| August 20, 2026 | 470.76M |
| August 19, 2026 | 489.80M |
| August 18, 2026 | 481.53M |
| August 17, 2026 | 428.44M |
| August 14, 2026 | 448.83M |
| August 13, 2026 | 430.94M |
| August 12, 2026 | 485.76M |
| August 11, 2026 | 390.36M |
| August 10, 2026 | 406.51M |
| August 07, 2026 | 373.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
| Savara, Inc. | 771.40M |
| Vericel Corp. | 1.986B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.28M |
| Total Expenses (Quarterly) | 22.28M |
| EPS Diluted (Quarterly) | -1.175 |
| Earnings Yield | -21.94% |
| Normalized Earnings Yield | -21.94 |